Menu Search
Equities

Abbott Laboratories

ABT:NYQ

Abbott Laboratories

Actions
Health CareMedical Equipment and Services
  • Price (USD)114.88
  • Today's Change-3.25 / -2.75%
  • Shares traded5.99m
  • 1 Year change+13.74%
  • Beta0.7178
Data delayed at least 15 minutes, as of Sep 19 2024 00:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 12-Sep-24
Select bar for recommendation details.
Recommendations12-Sep-24
Buy7
Outperform12
Hold7
Sell0
Strong Sell0

Share price forecast in USD

The 21 analysts offering 12 month price targets for Abbott Laboratories have a median target of 125.00, with a high estimate of 143.00 and a low estimate of 105.23. The median estimate represents a 8.81% increase from the last price of 114.88.
High24.5%143.00
Med8.8%125.00
Low-8.4%105.23

Dividends in USD

In 2023, Abbott Laboratories reported a dividend of 2.04 USD, which represents a 8.51% increase over last year. The 10 analysts covering the company expect dividends of 2.16 USD for the upcoming fiscal year, an increase of 5.98%.
Div growth (TTM)8.51%
More ▼

Earnings history & estimates in USD

On Jul 18, 2024, Abbott Laboratories reported 2nd quarter 2024 earnings of 1.14 per share. This result was in line with the consensus of the 20 analysts following the company and exceeded last year's 2nd quarter results by 5.56%.
The next earnings announcement is expected on Oct 16, 2024.
Average growth rate+2.16%
Abbott Laboratories reported annual 2023 earnings of 4.44 per share on Jan 24, 2024.
Average growth rate+10.26%
More ▼

Revenue history & estimates in USD

Abbott Laboratories had 2nd quarter 2024 revenues of 10.38bn. This bettered the 10.37bn consensus of the 19 analysts covering the company. This was 6.46% above the prior year's 2nd quarter results.
Average growth rate+1.01%
Abbott Laboratories had revenues for the full year 2023 of 40.11bn. This was 8.12% below the prior year's results.
Average growth rate+6.54%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.